Structural characterization of plant-derived hepatitis B surface antigen employed in oral immunization studies

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 4011-4021

  Smith, Mark L ^a,d   Richter, Lizabeth ^b,e   Arntzen, Charles J ^b,c   Shuler, Michael L ^a   Mason, Hugh S ^b,c  

^a Cornell University   (United States)

^b United States Department of Agriculture Agricultural Research Service and Boyce Thompson Institute for Plant Research   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d Large Scale Biology Corporation   (United States)

^e LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

Antigen structure; Edible vaccine; Hepatitis B surface antigen

Indexed keywords

EPITOPE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ANTIGEN STRUCTURE; ARTICLE; CELL CULTURE; COMMERCIAL PHENOMENA; COMPLEX FORMATION; CORRELATION ANALYSIS; CROSS LINKING; DISULFIDE BOND; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS B; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PLANT; PLANT CELL; POTATO; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VIRUS PARTICLE;

EID: 0242334122     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00268-8     Document Type: Article

References (40)

1. Tacket C.O., Mason H.S., Losonsky G., Estes M.K., Levine M.M., Arntzen C.J. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182(1):2000;302-305.
2. Tacket C.O., Mason H.S., Losonsky G., Clements J.D., Levine M.M., Arntzen C.J. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. 4(5):1998;607-609.
3. Richter L.J., Thanavala Y., Arntzen C.J., Mason H.S. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. Biotechnol. 18(3):2000;1167-1171.
4. Kong Q., Richter L., Yang Y.F., Arntzen C., Mason H.S., Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. U.S.A. 98(20):2001;11539-11544.
5. Kane M.A. Status of hepatitis B immunization programmes in 1998. Vaccine. 16(Suppl):1998;S104-S108.
6. Beutels P. Economic evaluations applied to HB vaccination: general observations. Vaccine. 16(Suppl):1998;S84-S92.
7. Hilleman MR. Plasma-derived hepatitis B vaccine: a breakthrough in preventive medicine. In: Ellis RW, editor. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker; 1993. p. 17-40.
8. Vyas G.N., Rao K.R., Ibrahim A.B. Australia antigen (hepatitis B antigen): a conformational antigen dependent on disulfide bonds. Science. 178:1972;1300-1301.
9. Sukeno N., Shirachi R., Yamaguchi J., Ishida N. Reduction and reoxidation of Australia antigen: loss and reconstitution of particle structure and antigenicity. J. Virol. 9(1):1972;182-183.
10. Sitrin RD, Wampler DE, Ellis RW. Survey of licensed hepatitis B vaccines and their production processes. In: Ellis RW, editor. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker; 1993. p. 83-102.
11. Mason H.S., Lam D.M.K., Arntzen C.J. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. U.S.A. 89(24):1992;11745- 11749.
12. Smith M.L., Mason H.S., Shuler M.L. Hepatitis B surface antigen (HBsAg) expression in plant cell culture: Kinetics of antigen accumulation in batch culture and its intracellular form. Biotechnol. Bioeng. 80:2002;812-822.
13. Ni M., Cui D., Einstein J., Narasimhulu S., Vergara C.E., Gelvin S.B. Strength and tissue specificity of chimeric promoters derived from the octopine and mannopine synthase genes. Plant J. 7(4):1995;661-676.
14. Smith M.L., Keegan M.E., Mason H.S., Shuler M.L. Factors important in the extraction, stability and in vitro assembly of the hepatitis B surface antigen derived from recombinant plant systems. Biotechnol. Prog. 18(3):2002;538-550.
15. Dogan B., Mason H.S., Richter L., Hunter J.B., Shuler M.L. Process options in hepatitis B surface antigen extraction from transgenic potato. Biotechnol. Prog. 16(3):2000;435-441.
16. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler E., Miller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature. 307(5947):1984;178-180.
17. Ellis R.W., Gerety R.J. Plasma-derived and yeast-derived hepatitis B vaccines. Am. J. Infect. Control. 17(3):1989;181-189.
18. Harford N., Cabezon T., Crabeel M., Simeon E., Rutgers T., De Wilde M. Expression of hepatitis B surface antigen in yeast. Dev. Biol. Stand. 54:1983;125-130.
19. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine. 8(Suppl):1990;S69-S73.
20. Hauser P., Voet P., Simoen E. Immunological properties of recombinant HBsAg produced in yeast. Postgrad. Med. J. 63(Suppl 2):1987;83-91.
21. Simon K., Lingappa V.R., Ganem D. Secreted hepatitis B surface antigen polypeptides are derived from a transmembrane precursor. J. Cell Biol. 107(6):1988;2163-2168.
22. Heermann KH, Gerlich WH. Surface proteins of hepatitis B viruses. In: McLachlan A, editor. Molecular biology of the hepatitis B virus. Boca Raton: CRC Press; 1991. p. 110-35.
23. Kitano K., Nakao M., Itoh Y., Fujisawa Y. Recombinant hepatitis B virus surface antigen p31 accumulates as particles in Saccharomyces cerevisiae. Biotechnology. 5(3):1987;281-283.
24. Patzer E.J., Nakamura G.R., Simonsen C.C., Levinson A.D., Brands R. Intracellular assembly and packaging of hepatitis B surface antigen particles occur in the endoplasmic reticulum. J. Virol. 58(3):1986;884-892.
25. Tanaka S., Miura K., Suzuki S. Ultrastructural changes in hepatocytes and clinico-pathological findings in chronic hepatitis B surface antigen carriers with special reference to cases with indirect hyperbilirubinemia alone. J. Clin. Electron Microsc. 10:1977;109-120.
26. Diminsky D., Schirmbeck R., Reimann J., Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine. 15(6-7):1997;637-647.
27. Traavik T., Kjeldsberg E., Siebke J.C. The effects of detergent treatment on the morphology of Australia antigen positive particles. Acta. Path. Microsc. B. 81:1973;37-42.
28. Roingeard P., Sureau C. Ultrastructural analysis of hepatitis B virus in HepG2-transfected cells with special emphasis on subviral filament morphogenesis. Hepatology. 28:1998;1128-1133.
29. Xu Z.C., Bruss V., Yen T.S.B. Formation of intracellular particles by hepatitis B virus large surface protein. J. Virol. 71(7):1997;5487-5494.
30. Berting A., Hahnen J., Kroger M., Gerlich W.H. Computer-aided studies on the spatial structure of the small hepatitis B surface protein. Intervirology. 38:1995;8-15.
31. Elliot AY, Morges W, Olson MG. Experience in manufacturing, testing, and licensing a hepatitis B vaccine produced by recombinant technology. In: Lubiniecki AS, Vargo SA, editors. Regulatory practice for biopharmaceutical production. New York: Wiley-Liss; 1994. p. 256-69.
32. Huovila A.P.J., Eder A.M., Fuller S.D. Hepatitis B surface antigen assembles in a post-ER pre-Golgi compartment. J. Cell Biol. 118(6):1992;1305- 1320.
33. Mangold C.M.T., Streeck R.E. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J. Virol. 67(8):1993;4588-4597.
34. Guerrero E, Galivanes F, Peterson D. Model for the protein rearrangement in HBsAg particles based on physical and chemical studies. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R. Liss; 1988. p. 606-13.
35. Wampler D.E., Lehman E.D., Boger J., McAleer W.J., Scolnick E.M. Multiple chemical forms of the hepatitis B surface antigen produced in yeast. Proc. Natl. Acad. Sci. U.S.A. 82(20):1985;6830-6834.
36. Hauser P, Thomas HC, Water J., et al. Induction of neutralizing antibodies in chimpanzees and in humans by a recombinant yeast-derived hepatitis B surface particle. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R. Liss; 1988. p. 1031-7.
37. Mangold C.M.T., Unckell F., Werr M., Streeck R.E. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch. Virol. 142(11):1997;2257-2267.
38. Eble B.E., Lingappa V.R., Ganem D. Hepatitis B surface antigen: an unusual secreted protein initially synthesized as a transmembrane polypeptide. Mol. Cell. Biol. 6(5):1986;1454-1463.
39. Petre J., Van Wijnendaele F., De Neys B.et al. Development of a hepatitis B vaccine from transformed yeast cells. Postgrad. Med. J. 63(Suppl 2):1987;73-81.
40. Mishiro S., Imai M., Takahashi K.et al. A 49,000-dalton polypeptide bearing all antigenic determinants and full immunogenicity of 22-nm hepatitis B surface antigen particles. J. Immunol. 124(4):1980;1589-1593.